Kalaris Therapeutics Inc. (NASDAQ:KLRS) Stock Rated “Moderate Buy” by Wall Street Brokerages

Posted by Stanley Muller on Oct 27th, 2026

Kalaris Therapeutics Inc. (NASDAQ:KLRS – Get Free Report) has earned a consensus rating of “Moderate Buy” from the seven brokerages that are presently covering the stock, Marketbeat reports. One analyst has rated the stock with a sell recommendation and six have given a buy recommendation to the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $18.75.

A number of equities analysts recently issued reports on the company. Weiss Ratings lowered Kalaris Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday. Wall Street Zen downgraded Kalaris Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, September 13th.

Read Our Latest Analysis on Kalaris Therapeutics

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. Velan Capital Investment Management LP lifted its holdings in shares of Kalaris Therapeutics by 38.9% during the second quarter. Velan Capital Investment Management LP now owns 25,000 shares of the company’s stock worth $102,000 after purchasing an additional 7,000 shares during the period. Connor Clark & Lunn Investment Management Ltd. purchased a new stake in Kalaris Therapeutics in the second quarter valued at approximately $122,000. WealthTrust Asset Management LLC purchased a new stake in Kalaris Therapeutics in the first quarter valued at approximately $72,000. Stonepine Capital Management LLC purchased a new stake in Kalaris Therapeutics in the second quarter valued at approximately $122,597. Finally, Pale Fire Capital SE acquired a new position in Kalaris Therapeutics in the 2nd quarter worth approximately $161,000. 66.05% of the stock is currently owned by hedge funds and other institutional investors.

Kalaris Therapeutics Trading Down 3.7%

NASDAQ:KLRS opened at $1.80 on Tuesday. Kalaris Therapeutics has a 12 month low of $1.78 and a 12 month high of $11.88. The firm has a fifty day simple moving average of $3.16 and a 200-day simple moving average of $5.61.

Kalaris Therapeutics (NASDAQ:KLRS – Get Free Report) last announced its quarterly earnings data on Tuesday, August 11th. The company reported ($0.48) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.50) by $0.02. On average, sell-side analysts predict that Kalaris Therapeutics will post -1.99 earnings per share for the current year.

Kalaris Therapeutics Company Profile

(Get Free Report)

Kalaris Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for retinal vascular diseases, a group of eye conditions that can lead to vision loss. The company’s research is aimed at addressing diseases in which abnormal blood-vessel growth or leakage damages the retina.

Kalaris Therapeutics’ lead investigational product candidate is KAL-101, an experimental therapy being developed for retinal diseases. The company is advancing KAL-101 through clinical development and evaluating its potential to provide a treatment option for patients with conditions requiring ongoing management of retinal vascular abnormalities.

The company’s activities primarily center on research, clinical development, and the potential commercialization of ophthalmic medicines.